A Market That Once Imported Its Technological Benchmarks

For many years, China's most technologically demanding medical device categories were shaped by international manufacturers. Global companies introduced advanced CT and MRI systems, high-end ultrasound, interventional implants and surgical equipment. Chinese manufacturers built domestic production capacity, learned to compete in established product categories and gradually expanded from manufacturing into engineering, system integration and original product development.

That development has been uneven. China has become highly competitive in several types of equipment and consumables, while imported products continue to play important roles in categories requiring long clinical track records, highly specialized components or mature global service networks.

Understanding the industry in 2026 requires separating three stages of development: manufacturing capability, domestic product substitution and clinically meaningful original innovation.

Phase One: Building Manufacturing and Distribution Capacity

China's early medical device growth benefited from the expansion of hospitals, public healthcare investment, electronics manufacturing and domestic supply chains. Manufacturers developed products in patient monitoring, medical consumables, imaging-related equipment, ultrasound and in vitro diagnostics, supported by local engineering and production capabilities.

The first commercial advantage was frequently lower production cost, local service coverage or faster adaptation to domestic customers. For hospitals outside major cities, affordable equipment and accessible after-sales support could be highly valuable. The industry's technical base expanded as companies invested in quality systems, components, software and more advanced clinical applications.

This phase established the commercial infrastructure needed to compete against imported devices. It did not automatically establish technological leadership.

Phase Two: Domestic Alternatives Enter High-Value Segments

During the 2010s and 2020s, Chinese companies increasingly moved into sophisticated markets: large medical imaging systems, cardiovascular implants, joint reconstruction, endoscopy and surgical robotics. Companies such as United Imaging Healthcare, Mindray, MicroPort, TINAVI and others developed distinct combinations of domestic engineering, clinical collaboration and international commercial activity.

In some segments, domestic manufacturers gained share by producing comparable systems at competitive prices. In others, they developed products specifically for Chinese clinical workflows, hospital budgets or physician preferences. Public procurement and volume-based purchasing also changed competitive conditions, especially in mature implantable-device categories.

The term import substitution is useful when describing the replacement of overseas-supplied devices by domestic alternatives. It says relatively little, however, about where an underlying invention originated or whether a product changes clinical practice. A competitively priced local replacement, a technically differentiated product and a new treatment concept are three different achievements.

Phase Three: Products and Therapies With Original Contributions

China's National Medical Products Administration (NMPA) operates a special review pathway for qualifying innovative medical devices. According to its 2025 medical device registration report, the agency approved 76 innovative medical devices in 2025, up approximately 17% from 2024. Across 2014–2025, it approved 391 devices through this innovation category, including 336 domestic and 55 imported products.

These are official regulatory figures. They document the development of a domestic innovation pipeline, but an NMPA innovative-device designation should not be treated as proof that every approved product is the first of its kind worldwide. Worldwide priority, clinical superiority and international commercialization each require different evidence.

Two examples show the range of contributions now associated with China.

Example 1: Total-Body PET Imaging — International Research Meets Chinese Engineering

The EXPLORER/uEXPLORER total-body PET/CT system was developed through collaboration involving the University of California, Davis and Shanghai-based United Imaging Healthcare. UC Davis researchers Simon Cherry and Ramsey Badawi conceived the system and led the scientific program; United Imaging supplied major engineering and manufacturing capabilities. The team unveiled the first human images in 2018.

Traditional PET scanners generally image the patient in separate sections. The total-body design enables simultaneous capture across a much larger axial field of view, with important implications for sensitivity, dynamic imaging and research applications. This example illustrates Chinese participation in a globally original medical imaging platform without misrepresenting the invention as exclusively Chinese.

Example 2: Pulmonary Artery Denervation — A China-Led Interventional Treatment Concept

In 2013, a team led by Shao-Liang Chen at Nanjing First Hospital published a first-in-human study of pulmonary artery denervation (PADN) for pulmonary arterial hypertension. The research explored catheter-based disruption of sympathetic nerve activity around the pulmonary arteries as a potential therapeutic mechanism.

A later multicenter, sham-controlled randomized trial in China, published in JACC: Cardiovascular Interventions in 2022, randomized 128 patients. At six months, the PADN group had a greater improvement in six-minute walk distance than the sham group, with an adjusted between-group difference of 33.8 meters. The trial also reported improvements in certain hemodynamic and clinical endpoints within its study population.

The distinction matters: clinical trial results support investigation of a novel treatment; they do not, by themselves, establish routine clinical adoption or a medical device's regulatory approval in every market. Nevertheless, this research is an example of a treatment idea developed and clinically investigated by a Chinese-led team, rather than a local imitation of an established imported product.

Surgical Robotics Shows Another Form of Innovation

China's surgical robotics industry offers a third, system-level example. Chinese developers now work across laparoscopic, orthopedic, neurosurgical, dental and natural-orifice platforms, as well as selected interventional categories. Their designs address instrument architecture, multi-arm control, clinical workflows, system integration, teleoperation and hospital operating costs.

The importance of this activity extends beyond the number of domestic manufacturers. China's hospital environment is creating opportunities to test different product designs and commercial models. Some manufacturers remain focused on the domestic market; others have obtained overseas authorizations and are building local support networks in international markets.

A robotics product can be technically original in one subsystem or workflow without being superior to every competing system. Clinical outcomes, maintainability, user training and cost per procedure remain essential tests of the innovation's value.

Why the Shift Matters for Global Manufacturers

The Chinese device industry now competes on several dimensions simultaneously: manufacturing cost, engineering capability, access to clinicians, product differentiation, speed of iteration and international certification. Global manufacturers may face Chinese competitors at home while also finding Chinese companies to be potential research, component or commercial partners.

The economic environment also presents constraints. Volume-based procurement can reduce product prices. Hospital capital budgets are finite. Medical service pricing and reimbursement affect the adoption of advanced equipment. Companies building sophisticated systems must finance clinical evidence, field service and long-term software and hardware maintenance.

China's progression therefore should not be described as a finished transition from imitation to leadership. Import substitution remains important in some segments; original research and technology platforms are already visible in others. These developments can coexist within the same company or product category.

For international readers, the useful question is increasingly specific: Which Chinese companies have a verified, differentiated technology, credible clinical evidence, relevant regulatory authorization and the ability to support customers outside China?

Further company background is available in MedChina's 20 Chinese MedTech Companies Global Executives Should Know in 2026.

October 28, 2026